Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it getting
08:51am, Tuesday, 19'th Mar 2024
AstraZeneca PLC (LSE:AZN) is acquiring Canada's Fusion Pharmaceuticals for $2.4 billion, in a bid to effectively 'keep up with Joneses' as it seeks to challenge Novartis, which is blazing a trail in t
AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion
03:45am, Tuesday, 19'th Mar 2024
AstraZeneca is buying Fusion Pharmaceuticals for $2.4 billion as the London-listed group looks to build its presence in cutting-edge cancer treatments.
AstraZeneca to buy Fusion Pharma in $2.4bln deal
03:34am, Tuesday, 19'th Mar 2024
AstraZeneca PLC (LSE:AZN) is acquiring clinical-stage oncology group Fusion Pharmaceuticals in a $2.4 billion (£1.9 billion) deal. The offer represents a massive 126% premium to Nasdaq-listed Fusion'
AstraZeneca to buy Fusion Pharma for $2 billion in cash
03:11am, Tuesday, 19'th Mar 2024
AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash to boost its oncology portfolio.
AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Monday, 18'th Mar 2024
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AstraZeneca to cap US out-of-pocket costs for inhalers to $35
07:14am, Monday, 18'th Mar 2024
AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products for chronic lung disease and asthma to $35 per month, starting June, in the United States.
7 Mega-Cap Stocks That Can Turn $10,000 Into $1 Million
11:16am, Friday, 15'th Mar 2024
By definition, mega-cap stocks are those which possess a market capitalization above $200 billion. So, investors seeking to turn $10,000 into $1 million through Mega cap companies will be choosing fro
This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery
09:15am, Friday, 15'th Mar 2024
Investing in biopharmaceutical stocks comes with more risks than some other types of stocks.
AstraZeneca Amolyt Pharma takeover ‘sufficiently modest' - analysts
06:27am, Friday, 15'th Mar 2024
AstraZeneca PLC (LSE:AZN)'s £780 million takeover of France-based Amolyt Pharma on Thursday failed to tempt much of a reaction from Deutsche Bank analysts. According to the bank, the acquisition “i
AstraZeneca To Buy Amolyt Pharma for $1.05B To Expand Rare Disease Pipeline
12:50pm, Thursday, 14'th Mar 2024
AstraZeneca PLC (AZN) plans to acquire biotech firm Amolyt Pharma for $1.05 billion in cash, the drugmaker said Thursday, boosting its pipeline of drugs to treat rare diseases.
AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion
12:01pm, Thursday, 14'th Mar 2024
AstraZeneca (AZN) enters into an agreement to acquire Amolyt Pharma to strengthen its rare disease pipeline by adding the latter's late-stage hypoparathyroidism treatment candidate, eneboparatide.
AstraZeneca to buy France's Amolyt Pharma for £780m
03:43am, Thursday, 14'th Mar 2024
AstraZeneca PLC (LSE:AZN) has agreed to buy France-based Amolyt Pharma for $1.05 billion (£780 million) to strengthen the late-stage drug pipeline of its Alexion rare disease arm. Lyon-based Amolyt's
AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare diseases portfolio
03:15am, Thursday, 14'th Mar 2024
Drugmaker AstraZeneca said on Thursday it will acquire rare endocrine diseases-focused firm Amolyt Pharma for $1.05 billion in cash, in a bid to boost its rare diseases portfolio.
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
06:56pm, Wednesday, 13'th Mar 2024
Astrazeneca (AZN) reachead $67.58 at the closing of the latest trading day, reflecting a +0.27% change compared to its last close.
5 Reasons AstraZeneca Stock Can Rise In 2024
05:15pm, Friday, 08'th Mar 2024
AstraZeneca PLC has seen a modest 3% price rise in the past year, but there are positive factors that could drive price upside in 2024. The company has improved revenue guidance for 2024, after guidan
